72 related articles for article (PubMed ID: 11919393)
41. Chronic myeloproliferative disorders: the role of tyrosine kinases in pathogenesis, diagnosis and therapy.
Macdonald D; Cross NC
Pathobiology; 2007; 74(2):81-8. PubMed ID: 17587879
[TBL] [Abstract][Full Text] [Related]
42. Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system.
Tefferi A; Gilliland G
Best Pract Res Clin Haematol; 2006; 19(3):365-85. PubMed ID: 16781478
[TBL] [Abstract][Full Text] [Related]
43. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders.
Cross NC; Reiter A
Acta Haematol; 2008; 119(4):199-206. PubMed ID: 18566537
[TBL] [Abstract][Full Text] [Related]
44. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1.
Macdonald D; Reiter A; Cross NC
Acta Haematol; 2002; 107(2):101-7. PubMed ID: 11919391
[TBL] [Abstract][Full Text] [Related]
45. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
Hall J; Foucar K
Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
[TBL] [Abstract][Full Text] [Related]
46. Cytogenetic and molecular genetic aspects of childhood myeloproliferative/myelodysplastic disorders.
Hall GW
Acta Haematol; 2002; 108(4):171-9. PubMed ID: 12432214
[TBL] [Abstract][Full Text] [Related]
47. Atypical myeloproliferative disorders: diagnosis and management.
Tefferi A; Elliott MA; Pardanani A
Mayo Clin Proc; 2006 Apr; 81(4):553-63. PubMed ID: 16610578
[TBL] [Abstract][Full Text] [Related]
48. Cytogenetics of chronic myeloproliferative disorders and related myelodysplastic syndromes.
Adeyinka A; Dewald GW
Hematol Oncol Clin North Am; 2003 Oct; 17(5):1129-49. PubMed ID: 14560778
[TBL] [Abstract][Full Text] [Related]
49. Common features of myeloproliferative disorders with t(8;9)(p12;q33) and CEP110-FGFR1 fusion: report of a new case and review of the literature.
Mozziconacci MJ; Carbuccia N; Prebet T; Charbonnier A; Murati A; Vey N; Chaffanet M; Birnbaum D
Leuk Res; 2008 Aug; 32(8):1304-8. PubMed ID: 18096225
[TBL] [Abstract][Full Text] [Related]
50. The importance of cytogenetic and molecular analyses in eosinophilia-associated myeloproliferative neoplasms: an unusual case with normal karyotype and TNIP1- PDGFRB rearrangement and overview of PDGFRB partner genes.
Maccaferri M; Pierini V; Di Giacomo D; Zucchini P; Forghieri F; Bonacorsi G; Paolini A; Quadrelli C; Giacobbi F; Fontana F; Cappelli G; Potenza L; Marasca R; Luppi M; Mecucci C
Leuk Lymphoma; 2017 Feb; 58(2):489-493. PubMed ID: 27337990
[No Abstract] [Full Text] [Related]
51. Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review.
Savage N; George TI; Gotlib J
Int J Lab Hematol; 2013 Oct; 35(5):491-500. PubMed ID: 23489324
[TBL] [Abstract][Full Text] [Related]
52. t(5;12)(q31;p12). A clinical entity with features of both myeloid leukemia and chronic myelomonocytic leukemia.
Wessels JW; Fibbe WE; van der Keur D; Landegent JE; van der Plas DC; den Ottolander GJ; Roozendaal KJ; Beverstock GC
Cancer Genet Cytogenet; 1993 Jan; 65(1):7-11. PubMed ID: 8431918
[TBL] [Abstract][Full Text] [Related]
53. The New Clinicopathologic and Molecular Findings in Myeloid Neoplasms With inv(3)(q21q26)/t(3;3)(q21;q26.2).
Wang HY; Rashidi HH
Arch Pathol Lab Med; 2016 Dec; 140(12):1404-1410. PubMed ID: 27628325
[TBL] [Abstract][Full Text] [Related]
54. [Molecular bases of leukemia, MPD and MDS].
Kitamura T
Rinsho Ketsueki; 2009 Mar; 50(3):174-81. PubMed ID: 19352084
[No Abstract] [Full Text] [Related]
55. Reciprocal translocation involving 3q21 in an unusual myeloproliferative disorder with myelodysplastic features and prominent dysmegakaryopoiesis.
Cedrone M; Mecucci C; Burgio VL; Diverio D; Petti MC; Alimena G
Cancer Genet Cytogenet; 1991 Jan; 51(1):73-8. PubMed ID: 1984850
[TBL] [Abstract][Full Text] [Related]
56. The relationship between the myelodysplastic syndromes and the myeloproliferative disorders.
Bain BJ
Leuk Lymphoma; 1999 Aug; 34(5-6):443-9. PubMed ID: 10492067
[TBL] [Abstract][Full Text] [Related]
57. Myeloid Neoplasm with PCM1-PDGFRB Transcript Responded to Low-Dose Imatinib: One Case Report with Literature Review.
Wang Z; Wan L; Lin D; Li CW; Tian Z; Mi YC
Acta Haematol; 2022; 145(5):560-565. PubMed ID: 35340014
[TBL] [Abstract][Full Text] [Related]
58. Updates on eosinophilic disorders.
Tzankov A; Reichard KK; Hasserjian RP; Arber DA; Orazi A; Wang SA
Virchows Arch; 2023 Jan; 482(1):85-97. PubMed ID: 36068374
[TBL] [Abstract][Full Text] [Related]
59. Chromosome 1 abnormalities in myeloid malignancies: a literature survey and karyotype-phenotype associations.
Caramazza D; Hussein K; Siragusa S; Pardanani A; Knudson RA; Ketterling RP; Tefferi A
Eur J Haematol; 2010 Mar; 84(3):191-200. PubMed ID: 20002154
[TBL] [Abstract][Full Text] [Related]
60. Molecular markers guide diagnosis and treatment in Philadelphia chromosome-negative myeloproliferative disorders (Review).
Vladareanu AM; Müller-Tidow C; Bumbea H; Radesi S
Oncol Rep; 2010 Mar; 23(3):595-604. PubMed ID: 20126996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
